Yale Cancer Center | Strategic Alliance Partners

Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.

Roy S. Herbst, MD, PhD, discusses the rationale for exploring immunotherapy/TKI combinations like pembrolizumab plus lenvatinib in patients with non–small cell lung cancer, and outlined the different efforts that comprise the LEAP clinical trial program.

Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme, the most common and most aggressive type of malignant brain tumor.

Roy S. Herbst, MD, PhD, discusses the evolving treatment landscape of targeted therapies in non–small cell lung cancer.

A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.

New research led by Yale Cancer Center shows the creation of a next-generation CRISPR-Cas9 “off-switch” and precision tool to aid safe gene editing therapeutics in patients.

Roy S. Herbst, MD, PhD, was honored by the International Association for the Study of Lung Cancer in recognition for his years of dedication and invaluable service to the organization and the lung cancer community.

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Consortium seeks to advance underdeveloped area of brain cancer research, advance drug development, and improve treatment options for patients

Yale Cancer Center held its annual Conclave award ceremony virtually on February 15 to celebrate scientific and caregiver accomplishments in 2021

New research led by Yale Cancer Center scientists shows less than a third of older patients with chronic myeloid leukemia had optimal laboratory monitoring and only two-thirds were adherent to TKI therapy during the first year after diagnosis.

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.

New research led by Yale Cancer Center reveals young women with breast cancer and a family history of the disease, but no high penetrance germline mutations, have an increased number of rare germline variants in cancer relevant genes

The FDA approvals of several targeted therapies, such as sotorasib, amivantamab-vmjw, and mobocertinib, as well as immunotherapeutic strategies, such as adjuvant atezolizumab, represent significant advances made in 2021 for the treatment of patients with non–small cell lung cancer.

Two new studies by Yale Cancer Center reveal the structure of the molecule known as anaplastic lymphoma kinase, which is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors.

Several Yale Cancer Center faculty have authored chapters in a newly released book, A New Deal For Cancer: Lessons from a 50 Year War.

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

A new study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.

Barbara Burtness, MD, has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center.

Researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

A revolutionary new urine screening test that utilizes a novel Keratin 17 cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2021 Annual Virtual Meeting of the American Society of Clinical Oncology June 4-8.

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

Anne Chiang, MD, PhD, has been appointed an Executive Officer of the Southwest Oncology Group Cancer Research Network.

Jill Lacy, MD, Professor of Medicine at Yale Cancer Center, was named a Fellow of the American Society of Clinical Oncology.